Response to Dr Nikpour's letter

We thank Dr Nikpour for her comment¹ concerning our recent publication 'Remission in systemic lupus erythematosus: durable remission is rare'.²

We agree that the lupus low disease activity state (LLDAS) is associated with less long-term damage. We are convinced that true remission should be our ultimate treatment goal. For example, LLDAS allows up to 7.5 mg of prednisone daily, while it was shown that prednisone doses above 6 mg/day significantly increase the risk of later organ damage by 50%.³

Very few patients reach durable remission, regardless of defining remission on treatment or off treatment. Remission is a high bar to aim for with our current treatment strategies.

Theresa R Wilhelm,^{1,2} Laurence S Magder,³ Michelle Petri¹

¹Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

²Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup, Glostrup, Denmark

³Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland, USA

Correspondence to Theresa R Wilhelm, Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup, Nordre Ringvej 57, 2600 Glostrup, Denmark; theresa.rita.wilhelm@regionh.dk

Competing interests None.

Provenance and peer review Commissioned; internally peer reviewed.

CrossMark

To cite Wilhelm TR, Magder LS, Petri M. *Ann Rheum Dis* 2016;**75**:e80.

Accepted 5 October 2016

► <http://dx.doi.org/10.1136/annrheumdis-2016-210560>

Ann Rheum Dis 2016;**75**:e80. doi:10.1136/annrheumdis-2016-210593

REFERENCES

- 1 Nikpour M, on behalf of the Asia Pacific Lupus Collaboration. Response to: 'Remission in systemic lupus erythematosus: durable remission is rare' by Wilhelm *et al.* *Ann Rheum Dis* 2016;**75**:e79.
- 2 Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. *Ann Rheum Dis* 2016; Published Online First: 24 Aug 2016. doi:10.1136/annrheumdis-2016-209489
- 3 Thamer M, Hernán MA, Zhang Y, *et al.* Prednisone, lupus activity, and permanent organ damage. *J Rheumatol* 2009;**36**:560–4.